VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer.

from http://www.ventirx.com/about/index.html

Patents show all

53Applications36Issued

Clinical Trials show all

2Phase 12Phase 1/Phase 22Phase 2

SEC Filings show all

D4

Contact Information

1191 Second Avenue, Suite 1105
Seattle, WA 98101
United States

(206) 689-2259

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $104,502,51411-502014-09-23Operating

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2014-09-23$50,602,514VentureARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, MedImmune Ventures, Celgene
    2006-01-01$2,300,000Seed
    2010-01-13$25,000,000VentureMedImmune VenturesARCH Venture Partners, Frazier Healthcare Partners, Domain Associates
    2007-03-06$26,600,000VentureFrazier Healthcare PartnersDomain Associates, ARCH Venture Partners

    SEC Form D Funding Events

    DateOfferedSoldType
    2014-09-30$15,000,000$15,000,000Equity, Option to Acquire, Security to be Acquired
    2014-09-23$53,102,414$50,602,514Equity
    2012-03-08$25,000,002$18,750,001Equity
    2007-03-22UnknownUnknownOther (Paper Filing)

    Key Executives

    • Robert M. Hershberg, M.D., Ph.D.
      Executive Officer, Director
    • Patrick Heron
      Director
    • Nicole Vitullo
      Director
    • Steven Gillis, Ph.D.
      Director
    • Elliot Grossbard, M.D.
      Director
    • Atul Saran
      Director
    • Kent Snyder
      Director
    • Ron Laufer
      Director
    • Kathleen Fanning
      Executive Officer